SLC35A2

Across TCGA pan-cancer cohorts, SLC35A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC35A2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLC35A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC35A2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where SLC35A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.513	0.927	.007	17	view →
LUAD	DFS	Median	All	0.654	0.950	.005	14	view →
PDAC	OS	Median	III,IV	0.974	0.601	<.001	14	view →
UCEC	DFS	Tertile	III,IV	1.000	0.529	.049	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC35A2–LSCC (OS)

Open the LSCC breakdown →